Strides Pharma UK Limited is a small but fast growing pharmaceutical company based in Watford United Kingdom engaged in the acquisition, development, marketing and distribution of a wide range of generic medicines, as well as OTC brands. Growth at Strides is driven by a focus on quality excellence in every aspect of product development, manufacture and distribution. This quality emphasis has laid a foundation for Strides to grow, from modest beginnings in 1993, to be amongst one of the most reliable suppliers of pharmaceutical products in the UK today, with several NHS contracts and ongoing OLS agreements in place. Our heritage OTC brands have become the standard for treatment/ usage within their therapeutic segments and also demonstrate continued growth in the retail sector. Manufacturing of most of our generics is now carried out by our parent company Strides Shasun Limited at their world class manufacturing plants, based in Bengaluru India. Strides products add value to healthcare systems by providing high quality medicines that are affordable. With a diverse and rapidly growing product range, we cover a number of therapeutic segments. Each bottle contains 35 g mycophenolate mofetil in 110 g powder for oral suspension. 5 m L of the reconstituted suspension contains 1 g of mycophenolate mofetil. Cell Cept 1 g/5 ml powder for oral suspension is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. Use in renal transplant Adults Oral Cell Cept 1 g/5 ml powder for oral suspension should be initiated within 72 hours following transplantation. The recommended dose in renal transplant patients is 1 g administered twice daily (2 g daily dose), i.e. Paediatric population aged 2 to 18 years The recommended dose of Cell Cept 1 g/5 ml powder for oral suspension is 600 mg/madministered twice daily (up to a maximum of 2 g/10 m L oral suspension daily). As some adverse reactions occur with greater frequency in this age group (see section 4.8) compared with adults, temporary dose reduction or interruption may be required; these will need to take into account relevant clinical factors including severity of reaction. Paediatric population The recommended dose of 1 g administered twice a day for renal transplant patients and 1.5 g twice a day for cardiac or hepatic transplant patients is appropriate for the elderly. Renal impairment In renal transplant patients with severe chronic renal impairment (glomerular filtration rate ), outside the immediate post-transplant period, doses greater than 1 g administered twice a day should be avoided. No dose adjustments are needed in patients experiencing delayed renal graft function post-operatively. No data are available for cardiac or hepatic transplant patients with severe chronic renal impairment.
: The usual dose is 2 grams twice daily to be taken on rising and at bedtime, or 1 gram 4 times a day to be taken 1 hour before meals and at bedtime. For ease of administration, Antepsin Tablets may be dispersed in 10-15 m L of water. Four to six weeks' treatment is usually needed for ulcer healing, but up to twelve weeks may be necessary in resistant cases. In patients with severe or chronic renal impairment, Antepsin should be used with extreme caution and only for short-term treatment. Small amounts of aluminium are absorbed through the gastrointestinal tract and aluminium may accumulate. Aluminium osteodystrophy, osteomalacia, encephalopathy, and anaemia have been reported in patients with chronic renal impairment. For patients with impairment of renal function, laboratory testing such as aluminium, phosphate, calcium, and alkaline phosphatase is recommended to be periodically performed due to excretion impairment. The concomitant use of other aluminium containing medications is not recommended in view of the enhanced potential for aluminium absorption and toxicity. Bezoars have been reported after administration of sucralfate mainly to severely ill patients in intensive care units. Three clinical presentations of diarrhoeal disease may require treatment with antimicrobials: acute watery diarrhoea, invasive diarrhoea (dysentery) and persistent diarrhoea. Acute watery diarrhoea Most cases of acute watery diarrhoea are caused by rotavirus and do not require treatment with antimicrobials. Antimicrobial treatment is indicated, however, in cases due to infection with Vibrio cholerae. All cases of watery diarrhoea require measures for the prevention and treatment of dehydration. Cholera Cholera is caused by Vibrio cholerae and is characterized by severe acute watery diarrhoea. Several litres of fluid may be lost within a few hours, causing severe dehydration. The antimicrobial susceptibility of the local strains must be determined and multiple isolates tested during the course of an outbreak to confirm susceptibility. It is now recognized that as many as 90% of patients with cholera require no more treatment than prompt and adequate oral replacement of the water and electrolytes lost in the diarrhoeal stool and vomitus. Those who are severely dehydrated require intravenous fluids and antimicrobials.
Search the world's information, including webpages, images, videos and more. Google has many special features to help you find exactly what you're looking for. Co-pharma Ltd is a UK pharmaceutical company engaged in the acquisition, development, marketing and distribution of a wide range of generic medicines, as well as OTC.